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iELISAThe detection of anti-Streptococcus equi antibodies in the blood serum of horses can assist with the iden-
tiﬁcation of apparently healthy persistently infected carriers and the prevention of strangles outbreaks.
The aim of the current study was to use genome sequencing data to develop an indirect enzyme linked
immunosorbent assay (iELISA) that targets two S. equi-speciﬁc protein fragments. The sensitivity and
speciﬁcity of the antigen A and antigen C iELISAs were compared to an SeM-based iELISA marketed by
IDvet – diagnostic Vétérinaire (IDvet). Individually, each assay compromised speciﬁcity in order to
achieve sufﬁcient sensitivity (SeM iELISA had a sensitivity of 89.9%, but a speciﬁcity of only 77.0%) or sen-
sitivity to achieve high speciﬁcity. However, combining the results of the antigen A and antigen C iELISAs
permitted optimisation of both sensitivity (93.3%) and speciﬁcity (99.3%), providing a robust assay for the
identiﬁcation of horses exposed to S. equi.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license. Introduction
Strangles, caused by Streptococcus equi subspecies equi (S. equi),
is the most frequently diagnosed infectious disease of horses
worldwide with over 600 outbreaks identiﬁed each year in the
UK alone (Parkinson et al., 2011). The disease is characterised by
abscessation of the lymph nodes of the head and neck. Abscesses
formed in the retropharyngeal lymph nodes usually rupture into
the guttural pouches, which drain via the nostrils leading to the
classical mucopurulent nasal discharge associated with strangles.
However, the purulent material in the guttural pouches of a pro-
portion of animals fails to drain completely, enabling live S. equi
to persist in horses that have recovered from the acute disease
for up to several years in the absence of obvious clinical signs
(Newton et al., 1997). S. equi periodically sheds from these persis-
tently infected carrier horses, allowing transmission to naïve indi-
viduals and new outbreaks of disease. The persistence of S. equi in
the guttural pouches of horses is associated with follicular hyper-
plasia, suggesting that it may be possible to detect a measurable
antibody response (Waller and Jolley, 2007).The immunogenic SeM protein binds ﬁbrinogen, and IgG4 and
IgG7 sub-classes resulting in an anti-phagocytic activity (Bosch-
witz and Timoney, 1994; Meehan et al., 1998, 2001; Lewis et al.,
2008). Although mice vaccinated with SeM were protected from
intraperitoneal challenge (Meehan et al., 1998), no protection
was conferred to horses (Sheoran et al., 2002). Vaccination with
SeM-containing vaccines has been linked with complications such
as purpura haemorrhagica (Pusterla et al., 2003) and the perceived
risk of this often fatal complication led to the development of a
SeM-based indirect enzyme-linked immunosorbent assay (iELISA)
for the identiﬁcation of horses with high anti-SeM antibody levels
pre-vaccination with SeM-containing vaccines. This iELISA has
subsequently been exploited for the identiﬁcation of horses in-
fected with S. equi, with high antibody titres being suggested to
indicate disseminated disease, known as bastard strangles,
although no sensitivity or speciﬁcity data have been published to
date (Sweeney et al., 2005).
The SeM protein was also thought to be restricted to S. equi
(Galan and Timoney, 1988; Timoney et al., 1997), but a homologue,
SzM, in S. zooepidemicus was identiﬁed that shares near identity
with SeM across the C-terminal two-thirds of this protein (Kelly
et al., 2006). Pre-incubating sera with heat-killed S. zooepidemicus
can remove cross-reactive antibodies to SzM prior to the detection
of SeM-speciﬁc antibody responses (Davidson et al., 2008). Such a
process, although successful in reducing assay background, has not
Fig. 1. Comparison of the three iELISA assays. The mean% assay result relative to the
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be based on full length SeM despite the potential for the reporting
of false positive results.1,2
We exploited the S. equi strain 4047 (Se4047) and S. zooepidem-
icus strain H70 (SzH70) genome sequences to identify fragments of
surface exposed or secreted proteins that were restricted to S. equi
(Holden et al., 2009). We report here the application of N-terminal
recombinant protein fragments of SEQ2190 (antigen A) and SeM
(antigen C), for the development of an iELISA for the detection of
a S. equi-speciﬁc antibody response. The performance of the anti-
gen A and antigen C iELISAs relative to a whole SeM-based iELISA
for the identiﬁcation of horses exposed to S. equi was determined.
Materials and methods
Production of recombinant antigen A and antigen C
The 50 regions of the SEQ2190 and SeM genes that are restricted to S. equi were
ampliﬁed by PCR from Se4047 chromosomal DNA with Phusion polymerase (NEB)
and the primers 50 595equiunique (CCCGGATCCTAATGAAAAGCGATGCCAAAAAGG)
and 30 595equiunique (AAAGAATTCTTAGGTTCTAGCCTTAGCTTC) or 50 MPEP1
(AAAGGATCCTAAAATCTCAACAAGAAATG) and 30 MPEP1 (TTTGAATTCTTACATCT-
TAGCTGCTTTTTC), respectively (BamHI/EcoRI restriction sites are underlined). The
PCR products were cloned into the BamHI/EcoRI sites of the pGEX-3X vector (GE
Healthcare). The resulting constructs, pGEX-2190 and pGEX-mpep1, contain N-ter-
minal fusions of antigen A and antigen C to a glutathione S-transferase (GST) tag
driven by a tac promoter. DH10B E. coli cells harbouring each plasmid were grown
at 37 C in 2  YT containing 50 lg/mL ampicillin. Once the cells reached an optical
density at 600 nm of 0.6, 1 mM isopropyl-b-D-thiogalactopyranoside was added to
the medium and the cultures were incubated for 4 h at 28 C. Cells were harvested
and lysed by digestion with lysozyme for 1 h at 4 C followed by sonication, and the
GST-antigen A and GST-antigen C fusions puriﬁed over glutathione Sepharose 4B
beads according to the supplier’s protocol (GE Healthcare).
Serum samples used for assay comparison
A serum set from 89 horses involved in outbreaks of strangles in the UK was
used to determine assay sensitivity. Nasopharyngeal or guttural pouch samples
from all of these horses were culture positive for S. equi at or shortly before the time
of sampling and all were regarded as ‘true positive’ samples.
A serum set from 139 Icelandic horses was used to determine assay speciﬁcity.
The Icelandic horse population is geographically isolated with virtually no import of
horses for over 1000 years. Consequently, Icelandic horses have remained free from
most common contagious diseases including equine inﬂuenza, equine rhinopneu-
monitis, equine herpesvirus (EHV-1), equine viral arteritis (EVA) and strangles.
Therefore, these serum samples were regarded as ‘true negatives’.
iELISA protocol
Ninety-six well Immulon 2HB Flat bottom microtitre plates were coated over-
night at 4 C with 200 ng of antigen A or antigen C per well. Plates were washed
with phosphate buffered saline containing 0.05% Tween 20 (PBST) and blocked with
PBST containing 1% non-fat milk (PBSTN) for 1 h at 37 C. Plates were washed with
PBST and 100 lL of test or control serum diluted 1/800 in PBSTN was added to the
appropriate well for 1 h at 37 C. Assays were run in duplicate. Plates were washed
with PBST and 100 lL of peroxidase-conjugated goat anti-horse IgG (Kirkegaard and
Perry Laboratories) diluted 1/600 in PBSTN was added to each well and the plates
incubated for 1 h at 37 C. Plates were washed with PBST, 100 lL of SureBlue re-
serve peroxidase substrate 3,30 ,5,50-tetramethylbenzidine (Kirkegaard and Perry
Laboratories) was added and the plate incubated for 10 min at 21 C. 100 lL of
0.18 M sulphuric acid was added and the optical density at 450 nm (OD450nm) mea-
sured. An OD450nm of P0.5 was considered to be a positive result for antigen A or
antigen C iELISAs and for the combined assay a sample was considered to be posi-
tive if either assay generated a positive result.
SeM iELISA protocol
Ninety-six well plates that were pre-coated with full-length recombinant SeM
were purchased from IDvet (Streptos ver 0212 GB). The iELISA assay was conducted
according to manufacturer’s instructions. Brieﬂy, test and control sera were diluted
1/200 in the dilution buffer provided. 100 lL of the appropriate diluted serum was
added to each well and the plate incubated for 1 h at 37 C. Assays were run incut-off for sera from Icelandic residents (n = 139) or from strangles outbreaks
(n = 89) was calculated for each of the iELISAs. Error bars show the 95% conﬁdence
interval. The Icelandic sera iELISA results for all of the assays were signiﬁcantly
different to those from strangles outbreaks (P < 0.0001).
1 See: http://www.idexx.com/view/xhtml/en_us/equine/reference-laboratories
testmenu/tests/s-equi-elisa.jsf.
2 See: http://www.id-vet.com/English/elisa_diagnostic_kit/horses/streptos_gb.htm/
.duplicate. Plates were washed, 100 lL of 1 conjugate added and incubated for 1 h
at 37 C. Plates were washed, 100 lL of substrate solution added and incubated for
10 min at 21 C in the dark. One hundred microlitres of stop solution were added to
each well and the OD450nm measured. Positive control sera generated an OD450nm of
>0.350 and the ratio of the OD450nm of positive to negative control sera was greater
than 3, in agreement with manufacturer’s guidelines. The percentage of sample
OD450nm relative to the positive control for each plate was calculated according to
manufacturer’s instructions. A percentage of P100 was considered positive.
Statistical analyses
To compare the iELISA results in a graphical format, the mean% assay result rel-
ative to the cut-off was calculated for the antigen A and antigen C assays by dividing
the iELISA result by 0.5 (the assay cut-off) and multiplying by 100.
The ability of the two tests to conﬁrm exposure to S. equi was investigated by
cross tabulating test result classiﬁcation (positive or negative) against the true
exposure status (gold standard diagnosis) based on the origin of the samples (bac-
teriologically conﬁrmed UK exposure for positives and resident Icelandic status for
negatives) and calculating sensitivity and speciﬁcity% values based on the following
deﬁnitions. Sensitivity% is represented by the proportion of presumed true positives
that are identiﬁed as positive by the test being evaluated, with (100% minus sensi-
tivity%) representing the proportion of false negative results detected by the test.
Speciﬁcity% is represented by the proportion of presumed true negatives that are
identiﬁed as negative by the test being evaluated, with (100% minus speciﬁcity%)
representing the proportion of false positive results detected by the test.
Data were also analysed using Student’s t test and Receiver Operating Charac-
teristics (ROC) in Stata12 software to assess sensitivity and speciﬁcity estimates
for all ‘% relative to assay positive control’ breakpoints within the data applied
against the gold standard diagnosis.Results
All three iELISA assays generated signiﬁcantly higher results
with sera from strangles outbreaks than from Icelandic resident
horses (P < 0.0001 for all three assays; Fig. 1). At the manufac-
turer’s cut-offs (100% relative to assay positive control), the SeM
iELISA correctly identiﬁed 80/89 positive and 107/139 negative
samples giving a sensitivity of 89.9% and speciﬁcity of 77.0%,
respectively (Table 1). The results for each serum sample across
all of the iELISAs are presented in Table S1 (Appendix A). ROC anal-
ysis identiﬁed that a breakpoint of 130% relative to the assay con-
trol correctly identiﬁed 72/89 positive and 135/139 negative
samples generating an optimal assay sensitivity and speciﬁcity of
80.9% and 97.1%, respectively with this sample set (Fig. 2).
The antigen A iELISA correctly identiﬁed 66/89 positive and
138/139 negative samples giving a sensitivity of 74.2% and speci-
ﬁcity of 99.3% (Table 1). The antigen C iELISA was less sensitive
Table 1
Ability of the antigen A + antigen C and ID.vet SeM serological tests to conﬁrm exposure to S. equi.
Sera from S. equi positive horses Sera from Icelandic resident horses Total n
Positive n (%) Negative n (%)
SeM
Positive 80 (89.9%) 32 112
Negative 9 107 (77.0%) 116
Total 89 139 228
Antigen A
Positive 66 (74.2%) 1 67
Negative 23 138 (99.3%) 161
Total 89 139 228
Antigen C
Positive 53 (59.6%) 0 53
Negative 36 139 (100%) 175
Total 89 139 228
Antigens A and C
Positive 83 (93.3%) 1 84
Negative 6 138 (99.3%) 144
Total 89 139 228
Fig. 2. Receiver Operator Characteristics curve for iELISA data generated using
Stata12 software to assess sensitivity and speciﬁcity estimates for all ‘% relative to
assay positive control’ cut-off points within the data applied against the gold
standard diagnosis. Sensitivity% is represented by the proportion of presumed true
positives that are identiﬁed as positive by the test being evaluated. Speciﬁcity% is
represented by the proportion of presumed true negatives that are identiﬁed as
negative by the test being evaluated, with (100% minus speciﬁcity%) representing
the proportion of false positive results detected by the test.
3 See: http://pubmlst.org/szooepidemicus/.
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and all 139 negative samples giving a sensitivity of 59.6% and spec-
iﬁcity of 100% (Table 1). Further analysis of assay breakpoints for
this sample set identiﬁed an optimal breakpoint for the antigen C
ELISA of 0.3, which correctly identiﬁed 64/89 positive samples
and all 139 negative samples, giving a sensitivity of 71.9% and
speciﬁcity of 100% (Fig. 2).
The combined antigen A + antigen C iELISA correctly identiﬁed
83/89 positive samples and 138 of 139 negative samples giving a
sensitivity of 93.3% and speciﬁcity of 99.3% (Table 1). Lowering
the breakpoint of the antigen C iELISA to an OD450nm of 0.3 did
not increase the sensitivity of the combined antigen A + antigen
C iELISA, which remained at 93.3%.
Discussion
The identiﬁcation of horses that possess a speciﬁc antibody re-
sponse to S. equi in the absence of clinical signs of disease using
appropriate iELISAs can direct further sampling strategies towards
the identiﬁcation and treatment of persistently infected carriersand the eradication of S. equi infection. However, it is essential that
these assays have excellent sensitivity and speciﬁcity to minimise
re-sampling and the associated costs. S. equi is endemic in the UK
horse population and even apparently healthy herds may contain
persistently infected carriers or exposed horses that would gener-
ate genuinely positive iELISA results. However, there have been no
outbreaks of strangles in Iceland and no import of horses is permit-
ted, making this an ideal negative population for the quantiﬁcation
of the speciﬁcity of strangles diagnostic assays.
Although the IDvet SeM-based iELISA assay was almost as sen-
sitive as the combined antigen A + antigen C iELISA (89.9% cf.
93.3%), it had a poorer speciﬁcity, falsely identifying 23.0% of sam-
ples from Icelandic horses as positive for S. equi. It is considered
that this level of misclassiﬁcation would incur an unacceptable le-
vel of additional intervention, which would be likely to affect long
term compliance with any screening programme based on such a
test. Increasing the breakpoint of the SeM iELISA to 130% increased
assay speciﬁcity to 97.1%, but at the expense of reduced sensitivity,
such that almost 1/5 true positive horses would be incorrectly
classiﬁed.
The misclassiﬁcation of horses based on the SeM iELISA was not
unexpected given that a homologue of SeM, SzM, which shares
near identity across its C-terminal two thirds, is encoded by
S. zooepidemicus (Kelly et al., 2006). Cross-reactivity of anti-SzM
antibodies, produced following infection of Icelandic horses with
S. zooepidemicus, with SeM in the IDvet assay provides one expla-
nation for false positive results and the higher mean Icelandic sera
result for the IDvet assay observed in Fig. 1.
The selection of protein fragments that are restricted to S. equi
on the basis of genome content generated a highly sensitive and
speciﬁc iELISA. The use of both antigen A and antigen C iELISA re-
sults beneﬁtted clinical interpretation by raising sensitivity from
74.2% and 59.6%, respectively to 93.3%. In the population of Icelan-
dic resident horses included in this study, the speciﬁcity of the
combined antigen A and antigen C iELISA was 99.3%, with only
one of 139 negative horses misclassiﬁed.
The international population of S. zooepidemicus is highly
diverse (Webb et al., 2008) with over 300 different multilocus se-
quence types identiﬁed to date.3 Although S. zooepidemicus is com-
monly isolated from the Icelandic horse population (S. Björnsdóttir
et al., unpublished data), the geographical isolation of these horses
suggests that the diversity of the Icelandic population of S. zooepi-
demicus strains is likely to be lower than in populations of horses
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presented in this study could decline in horse populations infected
with a more diverse array of S. zooepidemicus that may express
cross-reactive epitopes.
Although beyond the scope of the current study, it is known
that horses that have recovered from strangles are also likely to
generate positive iELISA test results for several months even if they
have eliminated S. equi infection. Following the resolution of clin-
ical signs the screening of all non-affected horses on the premises
by iELISA enables the identiﬁcation of horses that were inadver-
tently exposed to S. equi during the outbreak, or may be unknown
persistently infected carriers. The identity of any persistently in-
fected carriers can then be conﬁrmed by qPCR (Webb et al.,
2012) on testing three consecutive nasal swabs at weekly intervals
or a guttural pouch lavage from all convalescent horses and those
unaffected animals that were iELISA positive. Such a post-outbreak
process enables the elimination of S. equi from the resident popu-
lation and the prevention of recurrent cases of strangles.
Conclusions
The antigen A + antigen C combined iELISA is currently the best
available serological screening assay for evaluating horses’ expo-
sure to S. equi with adequately high levels of sensitivity and spec-
iﬁcity for use in eradication and health screening programmes.
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